Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients

15. november 2026 opdateret af: Wei Zhao, Shandong University

A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia

This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.

Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.

But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.

The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.

Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.

Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

118

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Shandong
      • Jinan, Shandong, Kina, 250000
        • Rekruttering
        • Shandong Provincial Public Health Clinical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år til 110 år (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 65 years;
  • Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:

Onset in the community setting;

At least one of the following clinical manifestations:

New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.

For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.

  • At least one of the following risk factors for drug-resistant pathogens:

Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;

  • Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment.
  • Expected length of hospital stay ≥ 72 hours;
  • Signed informed consent form.

Exclusion Criteria:

  • Highly suspected or confirmed fungal pneumonia or viral pneumonia;
  • Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others;
  • Patients with severe allergy to β-lactams and history of severe adverse reactions;
  • End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure;
  • Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT);
  • Any other conditions deemed ineligible for enrollment by investigators.

Post-randomization exclusion criteria:

  • Isolated fungal infection;
  • Isolated viral infection;
  • Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: guideline-based conventional dosing

Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days.

Eksperimentel: Model-guided optimized dosing

Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
The proportion of patients achieving the predefined pharmacodynamic (PD) target.
Tidsramme: up to 1 month
up to 1 month

Sekundære resultatmål

Resultatmål
Tidsramme
Clinical improvement rate after 3 days of empiric therapy
Tidsramme: Day 3
Day 3
Length of hospital stay
Tidsramme: through hospital discharge, an average of 2 weeks
through hospital discharge, an average of 2 weeks
Treatment success rate
Tidsramme: through hospital discharge, an average of 4 weeks
through hospital discharge, an average of 4 weeks
Adverse event (AE) incidence rate
Tidsramme: through end of study-drug treatment, an average of 7 days
through end of study-drug treatment, an average of 7 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. juli 2026

Primær færdiggørelse (Anslået)

31. maj 2027

Studieafslutning (Anslået)

31. maj 2027

Datoer for studieregistrering

Først indsendt

20. maj 2026

Først indsendt, der opfyldte QC-kriterier

15. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. november 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • SDU-2026-elePIP-001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .